Member Info for Shrek1st

Hello Tyke

I missed this first time but found the transcript. This answers the question regarding codes. I will put the link on for the transcript.

“Michael Schmainda: The GE agreement is obviously significant. Anytime you have an agreement with a major global player in healthcare, it's very exciting. It's significant in itself because this is a unique agreement in that they've taken us through an onboarding process.

They’ve integrated our products into their internal sourcing databases and product catalogues with unique GE part numbers. So everything has been internalized. It should result in a very streamlined selling process and faster sales cycles.”

https://www.proactiveinvestors.co.uk/companies/news/1061314/iq-ai-subsidiary-imaging-biometrics-expands-ge-partnership-adds-board-member-icymi-1061314.html

Right back to the weekend

Cheers

Shrek

Hi Tyke,

I think we deserve some good luck and an improvement in fortunes. The GE news is great on its own, the addition of Al Musella to the board is even better in my view. Fingers crossed for the phase 1 results in the new year.

Anyway good weekend all,

Cheers

Shrek

Hi Tyke,

I think you are correct in that it will form part of software bundles that are offered.

This is a link to the GE site, no pricing but it gives a flavour.

https://www.gehealthcare.com/products/magnetic-resonance-imaging/effortless-imaging-ai-mri-solutions

Cheers

Shrek

Evening all,

This is an interview with our new director. It’s a few years old, however I found it interesting nonetheless with lots of information I was unaware of.

https://2ndchance2live.com/the-man-behind-the-musella-foundation/

Cheers

Shrek

“The revised agreement aims to accelerate the adoption of IB's innovative imaging solutions, benefiting healthcare providers and patients alike”.

Evening all,

The MCW is presenting at the Society for Neuro Oncology (SNO) meeting in Houston later this month.

I searched for Kathleen Schmainda first and got this:-

NIMG-64

Survival implications of postoperative restricted diffusion in high-grade glioma and limitations of intraoperative MRI detection

Daniel Aaronson, Brandon Laing, Ishan Singhal, Timothy Boerger, Ryan Beck, Kathleen Schmainda, Wade Meuller, Max Krucoff

Medical College of Wisconsin, Milwaukee, USA

SESSION DETAILS

Poster and Networking Session

Hall B3

7:30-9:30pm

Friday, 22 November, 2024

https://virtual.oxfordabstracts.com/event/18018/submission/1039

I then searched for Jennifer Connelly and got these results:

AUTHOR, AUTHOR, PRESENTING AUTHOR

Jennifer Connelly

TITLE

Mesenchymal-type genetic mutations are likely pre-requisite for glioblastoma to metastasize outside the central nervous system: an original case series and systematic review of the literature

Jennifer Connelly (author)

TITLE

Long-term survival and patterns of progression in patients with newly diagnosed glioblastoma treated with or without Tumor Treating Fields (TTFields) in a real-world setting

Jennifer Connelly (author)

TITLE

Voxel-wise survival analysis in glioblastoma: Tumor probability maps reveal critical regions near white matter tracts

Jennifer Connelly Connelly (author)

TITLE

Comparative analysis of long-term glioblastoma survivors using machine learning generated radio-pathomic metrics

Jennifer Connelly (author)

TITLE

Machine learning-generated whole-brain radio-pathomic tumor probability maps within contrast-enhancement stratify survival in glioblastoma patients undergoing gross-total resection

Jennifer Connelly (author)

TITLE

The impact of standard-of-care treatment on the relationship between cell density and SOX2 positivity in glioblastoma patients at autopsy

Jennifer Connelly (author)

TITLE

Sex differences in SOX2 glioblastoma expression outside MRI-defined contrast enhancement at autopsy

Jennifer Connelly (author)

TITLE

Outcomes of patients with isocitrate dehydrogenase-mutant WHO grade 4 astrocytoma treated with Tumor Treating Fields (TTFields) therapy: a real-world analysis

Jennifer M. Connelly (presenter)

I was looking for something trial related, however I can’t fault the workrate of the scientists. If anyone wants to look, go into the conference site and use the search function within. I tried the company name but that didn’t work well so there is a good chance I have missed something. If I get more time I will look again.

Cheers

Shrek

Hi Tyke that’s exactly what I was after. Will keep looking when I have time. There is a seminar on Friday that could be interesting and I hope they release some coverage afterwards. Right back to painting.

Gallium Maltolate for Treatment of Glioblastoma: Bench to Bedside and Back Again

Presenter:

Casey Zoss, Graduate Student

Schmainda Lab, Department of Biophysics

Medical College of Wisconsin

Event Location

Biophysics Conference Room (MFRC 2063)

Cheers

Shrek

Hello all

Another journal article. Doesn’t look like I have full access as I wanted more details on what software they had used.

Anyway here is the link:

https://academic.oup.com/neuro-oncology/article/26/Supplement_8/viii210/7889807

Shrek

Hi Tyke,

Good weekend to you too. If it’s any consolation that was my 10k buy this morning. I should have waited. Hey ho another bit of learning.

All the best

Shrek

Good morning,

EAP has another search result:

https://reaganudall.org/expanded-access/expanded-access-gallium-maltolate-gam

Everyday is a school day as I hadn’t heard of them before.

This is from the about us section of their site:

“The Reagan-Udall Foundation for the Food and Drug Administration is an independent 501(c)(3) organization created by Congress “to advance the mission of the FDA to modernize medical, veterinary, food, food ingredient, and cosmetic product development, accelerate innovation, and enhance product safety.”

The Foundation embodies FDA’s vision of collaborative innovation to address regulatory science challenges of the 21st century and assist in the creation of new, applied scientific knowledge, tools, standards, and approaches the FDA needs to evaluate products more effectively, predictably, and efficiently, and thereby enhance the FDA’s ability to protect and promote the health of the American public. The Foundation serves as a crucial conduit between FDA and the public, providing a means for FDA to interact directly with stakeholders, including industry and consumers. The Foundation does not participate in regulatory decision-making or offer advice to FDA on policy matters”.

Have a good weekend.

Shrek

Good morning,

Found this on the EAP at UNC lineberger.

https://www.med.unc.edu/neurosurgery/unc-lineberger-brings-investigative-cancer-treatment-for-glioblastoma-patients-in-southeastern-us/

Cheers

Shrek

Good luck Gee, sorry to see you go.

Atb

Shrek

Https://www.investegate.co.uk/announcement/rns/iq-ai-limited--iqai/iq-ai-issues-letter-to-shareholders/8485984

Hello all,

This is worth a read. The imaging side of the business is making progress, the academic work is impressive.

Multi-Site Benchmark Study for Standardized Relative Cerebral Blood Volume in Untreated Brain Metastases Using the DSC-MRI Consensus Acquisition Protocol

Sarah Kohn Loizzo et al. AJNR Am J Neuroradiol. 2024.

Here is the link:

https://pubmed.ncbi.nlm.nih.gov/39389776/

The company posted on twitter on the 4th October and actually got some engagement for a change. The back and forth is interesting in relation to IB Neuro. Also the person asking the questions used to be an IB user but not currently.

The science and imaging products are successful at generating journal articles, however not so much at delivering a step change in sales revenue. I hope to be pleasantly surprised when the forthcoming shareholders letter is published.

Cheers

Shrek

Looking forward to the TR1 after that trade.

Good weekend all👍

Shrek

Good morning,

Just saw this on twitter

https://x.com/helixexp/status/1839567909489639498?s=46&t=U7xny3m_YwAtHvYTKn00XA

Cheers

Shrek

Good morning,

Here is the link to the recording of the webinar from Tuesday.

https://youtu.be/Nes42d2YeQ0

Shrek

I think it depends on the strength of the phase 1 results. If the findings are positive and worthy of a phase 2, then that would be the time for a deal in my view. The NIH published something on the cost of clinical trials and I think the median cost of a phase 2 was approximately $20m. Given our market cap, a deal is logical to allow progression.

Cheers

Shrek

Good spot Tyke👍

Yep clinical trial record updated today.

The company have put out a reminder tweet earlier for tomorrow’s webinar with Mike.

Cheers

Shrek

Quantitative DSC Perfusion Class Maps,​ “FTB” – Fractional Tumor Burden

24 September 2024 • 18:00 - 19:00

Online

Share this event

Details

Join us for our upcoming webinar on the functionality of Fractional Tumor Burden Maps. Discover how this advanced tool can enhance diagnostic accuracy and treatment planning.

Speakers (1)

Michael Schmainda

Here is the link

https://events.teams.microsoft.com/event/03860e8d-f781-4ec8-9537-65697eae0051@ba3144f9-19be-48de-a24b-d30d716b86ad?mc_cid=1112de9ed4&mc_eid=UNIQID

Good weekend all,

Shrek